MedTrace Logo

Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients

NCT03313661 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-08-27

No results posted yet for this study

Summary

Evaluation of the glycemic efficacy of cabergoline on diabetic patients

Conditions

Interventions

DRUG

Cabergoline

cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide

DRUG

Gliclazide

gliclazide (60-120 mg)

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Jouliana Atef Morcos, Msc · Faculty of Pharmacy, Tanta University, Egypt

  • Abla Mohamed Ebeid, Ph D · Faculty of Pharmacy, AL-Delta University, Gamasa, Egypt

  • Samy Abdel kader khodeir, Ph D · Tanta University

  • Gamal Abdel khalek Elazab, Ph D · Faculty of Pharmacy, Tanta University, Egypt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-10-14
Primary Completion
2020-10-31
Completion
2020-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03313661 on ClinicalTrials.gov